ArticleArthritis research & therapy2026
Characteristics of CLA⁺Tregs in rheumatoid arthritis and their potential as biomarkers of treatment response.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundThe newly discovered Treg subset (CLA+ Tregs) expressing cutaneous lymphocyte-associated antigen is associated with inflammatory conditions. This study elucidated the role of CLA+ Tregs in rheumatoid arthritis (RA) development and its responses to treatment.
methodsA total of 12 T cell subsets, together with total T cells, B cells, and NK cells were analyzed in 169 patients with RA and 114 healthy controls using flow cytometry. Autoantibodies were detected by ELISA. The logistic regression models were employed to assess the association between cell subsets and rheumatoid arthritis. Relationships between CLA+ Tregs and clinical variables were assessed.
resultsAmong the immune cell subsets analyzed, CLA⁺ Tregs were the most significantly reduced ones in patients with RA compared with healthy controls (OR 0.825 [0.764–0.891], p < 0.001). Decreased CLA⁺ Tregs were strongly correlated to active disease status (adjusted OR 0.814 [0.733–0.902], p = 0.004; AUC 0.916 [0.869–0.963], p < 0.001). Decreased CLA+ Tregs were associated with higher swollen joint count, tender joint count and DAS28 scores, as well as systemic involvements, including interstitial lung disease (ILD), anemia, fever, and skin vasculitis. Additionally, rheumatoid factor (RF) and anti-mutated citrullinated vimentin antibody (anti-MCV) were correlated to lower CLA+ Tregs. Compared to baseline prior treatment, CLA+ Tregs increased significantly in RA patients, accompanied by improvements in disease activity (median, 9.60% vs. 18.80%, p = 0.044; 3.41 cells/µL vs. 7.86 cells/µL, p = 0.011, respectively).
conclusionsThe results demonstrated a significant reduction of CLA+ Tregs in active RA, especially in patients with systemic damages. Recovery of CLA+ Tregs may predict therapeutic responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.